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1 - ABSTRACT / RESUMEN 
ABSTRACT: Despite improvements achieved in recent years, treatment of Hepatitis C still 
remains a challenge in some cases, posing the need to find new drugs against the HCV 
(Hepatitis C Virus). Some compounds which exhibit a high antiviral activity in primary 
screening do not succeed due to low activity in vitro, low solubility in water or high toxicity. 
Encapsulation of these compounds in nanocarriers could be a solution, and it may provide 
new therapeutic options against HCV. Among the different nanomaterials currently used as 
drug carriers, amphiphilic Janus dendrimers stand out due to their ability to form 
hydrosoluble aggregates with a lipophilic core. In this work, a new lipophilic dendron based 
on bis-GMPA has been synthesized. Using this dendron, an amphiphilic Janus dendrimer 
has been obtained by means of a “click chemistry” reaction. This dendrimer can form micellar 
aggregates with a high drug load capacity and so, it was tested as carrier for three drugs 
against HCV: camptothecin, tiratricol and iopanoic acid. Both the aggregates and the 
drug/carrier complexes have been characterized in several ways: morphology and size have 
been determined by transmission electron microscopy and dynamic light scattering, and the 
thermodynamics of the interaction between the different drugs and the dendrimer has been 
studied by isothermal titration calorimetry. Finally, the results of encapsulation on viral 
inhibition and cell viability have been assessed using an appropriate hepatic cell line culture. 
No conclusive results have been obtained regarding antiviral activity of the drug-loaded 
dendritic aggregates. However, the preliminary data obtained from this work suggest that this 
nanocarrier could improve the activity of the encapsulated drugs without affecting cell 
viability. 
RESUMEN: A pesar de las mejoras conseguidas en los últimos años, el tratamiento de la 
Hepatitis C continúa siendo un reto en algunos casos, lo que plantea la necesidad de 
encontrar nuevos fármacos contra el VHC (Virus de la Hepatitis C). Ciertos compuestos que 
exhiben una alta actividad antiviral en screenings primarios no prosperan debido a baja 
efectividad in vitro, baja solubilidad en agua o alta toxicidad. Una posible solución es la 
encapsulación de estos compuestos en nanotransportadores, que podría proporcionar 
nuevas opciones terapéuticas contra el VHC. Entre los diferentes nanomateriales utilizados 
actualmente como transportadores de fármacos, los dendrímeros Jano anfifílicos destacan 
por su abilidad de formar agregados hidrosolubles con un núcleo lipídico. En este trabajo se 
ha sintetizado un nuevo dendrón lipófilo basado en bis-GMPA. A partir de este se ha 
obtenido un dendrímero Jano anfifílico mediante una reacción de “química click”. Este 
dendrímero puede formar agregados micelares con una alta capacidad de carga de fármaco, 
de modo que ha sido probado como transportador para tres fármacos contra el VHC: 
camptotecina, tiratricol y ácido iopanoico. Tanto los agregados como los complejos 
fármaco/dendrímero han sido caracterizados de varias maneras: la morfología y el tamaño 
se han determinado por microscopía de transmisión electrónica y dispersión dinámica de 
luz, y los parámetros termodinámicos de la interacción entre los diferentes fármacos y el 
dendrímero se ha estudiado por calorimetría isotérmica de titulación. Finalmente, se han 
evaluado los resultados de la encapsulación sobre la inhibición viral y la viabilidad celular, 
utilizando un cultivo de una línea celular hepática apropiada. No se han obtenido resultados 
concluyentes con respecto a la actividad antiviral de los complejos fármaco/dendrímero. Sin 
embargo, los datos preliminares obtenidos en este trabajo sugieren que este 
nanotransportador podría mejorar la actividad de los fármacos encapsulados sin afectar a la 
viabilidad celular.      
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2 - INTRODUCTION 
In recent years, the development of new therapies has significantly improved the outlook of 
illnesses which used to be life-compromising. One of these is Hepatitis C. This disease is 
caused by the Hepatitis C virus (HCV), and can range in severity from an asymptomatic 
acute infection to a chronic disease. The latter is responsible in many cases for cirrhosis, 
hepatocellular carcinoma, and chronic kidney disease[1]. Nowadays, it is estimated that 
chronic HCV infection affects around 71 million people around the world, according to the 
World Health Organization[2].  
Hepatitis C virus (HCV) is a hepatotropic, enveloped, positive-sense single-stranded RNA 
virus of the Flaviviridae family. Its genome has an open reading frame and encodes a single 
polyprotein of approximately 3000 amino acids, which needs to be processed by at least two 
host cellular peptidases and two viral peptidases (NS2 and NS3/4A)[3]. The serin protease 
NS3/4A has been commonly used as a pharmacological target, along with NS5A (plays an 
important role in viral replication, assembly and cell signaling) and the RNA polymerase 
NS5B. 
Current treatments for Hepatitis C are mainly based on combined therapies of what are 
called direct-acting antiviral agents (DAAs), for instance, the protease inhibitor simeprevir, 
the polymerase inhibitor sofosbuvir, or the NS5A inhibitors daclatasvir and ledispavir[4]. 
These are more specific than the previously used regimens, based on IFN-α and pegylated 
IFN-α, and can act against more than one viral genotype, succeeding to cure a high 
percentage of the cases while presenting a lower incidence of adverse events. 
Nevertheless, approximately 400000 people die each year from Hepatitis C or complications 
associated to the chronic form of the disease[2]. For this reason, HCV infection is still a major 
health problem which needs to be addressed. The limitations of current treatments include 
the appearance of resistances and the low tolerability of certain drugs. This together with the 
limited access to diagnosis and treatment in certain places of the world where Hepatitis C is 
prevalent puts forth the need for an ongoing investigation aimed at the discovery of new 
therapeutic options. 
In previous works carried out in our research group, several compounds with anti-HCV 
activity were identified: camptothecin, 3,3’,5-triiodothyroacetic acid (tiratricol) and iopanoic 
acid. They are allosteric inhibitors of the HCV NS3 protease that bind to the Zn2+-free form of 
the enzyme, which is partially unfolded, stabilizing it[5]. In this way, they trap NS3 protease in 
its inactive conformational state. These compounds were identified by means of experimental 
ligand screenings[6][7]. 
Figure 1: Skeletal formulas of camptothecin (A), tiratricol (B) and iopanoic acid (C). 
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Although these drugs are effective inhibitors of the NS3 protease, they exhibit several issues 
that needed to be improved. Camptothecin presents poor water solubility, low plasmatic 
stability and severe toxicity. Tiratricol and iopanoic acid have been seen to have low activity 
in cell assays (in vitro), which is thought to be due to hindered cell internalization. 
Consequently, these compounds would have initially been discarded as possible anti-HCV 
therapies.  
Nevertheless, the pharmacokinetic properties of these compounds can be acted upon in 
order to solve the problems they present. It is here that nanomedicine plays a key role. The 
development of different kinds of nanomaterials as drug carriers has made it possible to 
increase the solubility and stability of the therapeutic compounds in the physiological 
medium, resulting in an enhanced bioavailability. This allows doses to be reduced, thus 
minimizing the risk of harmful side effects. Furthermore, in vitro bioactivity may be rescued 
since encapsulation in a nanocarrier can improve the access of an active principle to the 
infected cell. For instance, encapsulation of tiratricol and iopanoic acid in γ-cyclodextrins was 
seen to increase the anti-HCV activity of these compounds[7]. 
Among the different nanomaterials used as platforms for drug delivery, dendrimers have 
gained a special interest over the past few decades. They are hyper-ramified polymers with a 
defined tree-like structure, made up of a certain number of repetitive units, depending on the 
generation and size of the dendrimer. They are practically monodisperse and present 
numerous peripheral groups that can be functionalized with different moieties. These 
characteristics make them more versatile and reproducible than other types of polymers[8]. 
The Liquid Crystals and Polymers Group, with which this project has been carried out, has 
specialized in the synthesis of different types of dendrimers for several applications, including 
drug and gene delivery. 
In particular, platforms based on Janus dendrimers offer interesting features to this effect. 
Janus dendrimers, which receive their name from the two-faced Roman god Janus, are 
formed by two dendritic blocks (dendrons) that can have different terminal groups and hence 
different properties[9]. If one of the dendrons is lipophilic and the other is hydrophilic, the 
result is an amphiphilic molecule with the ability to self-assemble in aqueous solutions. This 
often results in micellar aggregates or bilayers whose morphology generally depends on the 
size proportion between the hydrophilic and lipophilic dendrons[10]. 
A previous work was carried out in this group in which Janus dendrimers based on 2,2’-
bis(hydroxymethyl)propionic acid (bis-MPA) dendritic blocks were used as camptothecin 
carriers[11]. The bis-MPA molecule offers several advantages: it can be synthesized in bulk 
Figure 2: Schematic representation of a Janus dendrimer[9]. 
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quantities, it has reactive groups that can be functionalized with organic and inorganic 
moieties, and the dendritic structures derived from it can be water soluble, biocompatible and 
hydrolytically degradable[12]. In this case, glycine moieties were added to the periphery of the 
hydrophilic dendron in order to enhance cellular internalization of the resulting ammonium-
terminated aggregates. 
Following this research line, a new type of hydrophilic poly(esteramide) dendrons was 
designed as part of the PhD thesis of Dr. Alexandre Lancelot[13], carried out with the Liquid 
Crystals and Polymers group. These dendrons are based on 2,2’-
bis(glyciloxymethyl)propionic acid (bis-GMPA), and contain both internal and peripheral 
glycine moieties. The dendrimers synthesized as a combination of bis-GMPA hydrophilic 
dendrons and bis-MPA lipophilic dendrons show a much higher efficiency in encapsulating 
camptothecin than that of the dendrimers only based in bis-MPA. This can be explained by 
the potential formation of hydrogen bonds between the lactone, hydroxyl and ketone groups 
of the drug and the internal amide groups of the dendron. 
 
However, the resulting dendrimer/camptothecin conjugates fail to improve the cell viability 
and HCV inhibitory activity values obtained for free camptothecin. A reason for this may be 
the location of the drug in these aggregates. Since the glycine residues with which it interacts 
are part of the hydrophilic, more polar dendron, the drug is possibly located in a partially 




Figure 3: Comparison between the structures of hydrophilic dendrons of generation 2 based on 
bis-MPA (N3-[bisMPA,G2]-(NHBoc)4) and bis-GMPA (N3-[bisGMPA,G2]-(NHBoc)4). The internal 
glycine moieties introduced in the bis-GMPA dendrons are circled in green. 
N3-[bisGMPA,G2]-(NHBoc)4 N3-[bisMPA,G2]-(NHBoc)4 
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3 - OBJECTIVES AND WORK PLAN 
Taking into account the antecedents described in the Introduction, two main objectives for 
this work were proposed: 
1. The synthesis and characterization of a new kind of amphiphilic Janus dendrimer 
based on a bis-MPA hydrophilic dendron and a bis-GMPA lipophilic dendron. This 
design aims to solve the limitations of the aforementioned dendrimers, by inserting the 
stabilizing glycine moieties in a more lipophilic environment which may better preserve 
the activity of the drugs. 
2. The study of the transport properties of the aggregates formed with this new 
dendrimer as carriers of the three compounds previously described 
(camptothecin, tiratricol and iopanoic acid), so as to assess their effectiveness in 
reducing drug cytotoxicity and maintaining or enhancing the in vitro antiviral activity of 
these compounds. 
 
In order to reach these objectives we followed this sequential work plan: 
• Synthesis and characterization of a new lipophilic dendron based on bis-GMPA. 
• Synthesis and characterization of an amphiphilic Janus dendrimer formed by the bis-
GMPA lipophilic dendron and a bis-MPA hydrophilic dendron functionalized with 
ammonium terminal groups. 
• Determination of the ability to self-assemble in water of the dendrimer and 
characterization of the size and morphology of the resulting nanoaggregates. 
• Encapsulation of camptothecin, tiratricol and iopanoic acid in the nanoaggregates: 
• Quantification of the amount of drug encapsulated and determination of the 
encapsulation efficiencies. 
• Study of the interaction between the drugs and the dendrimer. 
• Characterization of the size and morphology of the dendrimer/drug conjugates. 
• In vitro determination of the effects on viral replication and cell viability of the dendritic 




4 - MATERIALS AND METHODS 
4.1 - Synthesis and characterization 
Solvents were purchased from Scharlab, S.L. All reagents and camptothecin, were 
purchased from Sigma-Aldrich or Acros and were used without further purification. TBTA 
(tris(benzyltriazolylmethyl)amine), saturated solution of HCl in ethyl acetate, DPTS (4-
(dimethylamino)pyridium 4-toluenesulfonate) and bis-MPA monomer were prepared in our 
laboratory. 
1H NMR and 13C NMR experiments were performed using a Bruker AV-400 (1H: 400 MHz, 
13C: 100 MHz) spectrometer. The chemical shifts are given in ppm relative to TMS 
(tetramethyl silane) and the coupling constants in Hz; the solvent residual peak was used as 
internal standard. Mass spectrometry (MS) was performed on a Bruker Microflex system 
employing the ESI or the MALDI-TOF technique with nitrogen laser (337 nm) and dithranol 
as matrix. Infrared spectra were obtained on a Bruker Vertex 70 spectrophotometer in ATR 
(attenuated total reflection) mode. Gel permeation chromatography was performed on a 
Waters e2695 Alliance system with two Styragel columns HR4 and HR1 (500 and 104 Å of 
pore size) in series and a Waters 2424 evaporation light scattering detector with a sample 
concentration of 1 mg/mL. The solvent used was tetrahydrofuran (HPLC grade) with a flow 
rate of 1 mL/min at 35° C; PMMA (poly(methyl methacrylate) was used as the standard for 
calibration. Elemental Analysis (EA) was performed with a Perkin-Elmer 2400 series II 
microanalyser. 
 
Synthesis and characterization of the lipophilic dendron (≡-[bisGMPA,G1]-(C17)2): 
functionalization of the dendron with stearic acid (C17 alkyl chains) 
 
Figure 4: Skeletal structure of ≡-[bisGMPA,G1]-(C17)2. 
 
Stearic acid (2.37 g, 8.34 mmol, 3 eq.), 4-(dimethylamino) pyridine (DMAP) (0.27 g, 2.22 
mmol, 0.8 eq.) and 1-hydroxybenzotriazole (HOBt) (1.28 g, 8.34 mmol, 3 eq.) were dissolved 
intro anhydrous dichloromethane (86 mL). The reaction mixture was stirred under argon 
atmosphere. Dicyclohexylcarbodiimide (DCC) (1.72 g, 8.34 mmol, 3 eq.) was dissolved into a 
minimal volume of anhydrous dichloromethane (4 mL) and added dropwise to the reaction 
mixture. ≡-[bisGMPA,G1]-(NH3+Cl-)2 (1 g, 2.78 mmol, 1 eq.; described in the Annex, pages 
36-38) was dissolved into 10 mL of anhydrous dimethyl sulfoxide, together with DMAP (0.68 
g, 5.56 mmol, 2 eq.). This mixture was then added dropwise to the aforementioned reaction 
mixture with a dropping funnel. The final reaction mixture was stirred at room temperature 
under argon atmosphere during 48 hours. A white precipitate appeared (N,N’-
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dicyclohexylurea), which was filtered off. The solvent was then evaporated under vacuum. 
The crude product was dissolved into a minimal volume of dichloromethane and purified by 
precipitation into cold acetone overnight. The precipitate was further purified through silica 
gel column chromatography (dichloromethane : methanol = 98 : 2). A brown solid was 
obtained (1856 mg, yield = 81.5%). 
Mw = 819.21 g/mol. 
1H NMR (400 MHz, CDCl3) δ (ppm): 6.16 (bs, 2H, -NH), 4.72 (d, J = 2.4 Hz, 2H, H-3), 4.32 
(m, 4H, H-7), 4.01 (d, J = 5.4 Hz, 4H, H-9), 2.50 (t, J = 2.4 Hz, 1H, H-1), 2.27 – 2.19 (m, 4H, 
H-11), 1.68 – 1.57 (m, 4H, H-12), 1.28 (s, 3H, H-6), 1.24 (d, J = 14.9 Hz, 56H, H-13), 0.87 (t, 
J = 6.8 Hz, 6H, H-14). 
13C NMR (100 MHz, CDCl3) δ (ppm): 173.69 (C-10), 171.80 (C-4), 169.76 (C-8), 75.57 (C-1), 
65.76 (C-7), 52.91 (C-3), 46.33 (C-5), 41.23 (C-9), 36.47 (C-11), 32.06 (C-13), 29.94 – 29.33 
(C-13’), 25.68 (C-12), 22.82 (C-13’’), 18.15 (C-6), 14.25 (C-14). 
FTIR (νmax/cm-1, ATR): 3294 (N-H st), 2955 and 2916 (C-H st), 1744 (C=O ester st), 1645 
(C=O amide st), 1555 (N-H δ), 1470 (CH2, CH3 δ), 1203 (C-O st). 
MS (ESI+) m/z (%): found 841.5 (100), calculated for [C48H86N2O8,Na]+ 841.63. 
EA (%): Found: C. 70.12; H. 10.45; N, 3.34. Calc. for C48H86N2O8: C, 70.37; H, 10.58; N, 
3.42.  
GPC: (ref PMMA): Mw 2340 g.mol-1;  Ð 1.04. 
 
Synthesis and characterization of the protected dendrimer ((NHBoc)8[bisMPA,G3]-
[bisGMPA,G1](C17)2): copper(I) azide-alkyne cyloaddition reaction (CuAAC) 
 
Figure 5: Skeletal structure of (NHBoc)8[bisMPA,G3]-[bisGMPA,G1](C17)2. 
 
 
Hydrophylic bis-MPA dendron of generation 3 (900 mg, 407 µmol, 1 eq.) and ≡-
[bisGMPA,G1]-(C17)2 (400 mg, 488 µmol, 1.2 eq.) were dissolved into dimethylformamide 
(DMF; 7 mL) in a Schlenk flask. The reaction mixture (azide-alkyne reaction mixture)  was 
subjected to 3 vacuum-argon cycles in order to remove the O2 and stirred under argon 
atmosphere at 45ºC. CuSO45.H2O (11.99 mg, 40.7 µmol, 0.1 eq.), L-ascorbate (16.13 mg, 
81.4 µmol, 0.2 eq.) and TBTA (27.58 mg, 40.7 µmol, 0.1 eq.) were dissolved into DMF (3 
mL) in a second Schlenk flask. This solution also underwent 3 vacuum-argon cycles and was 
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then stirred at 45º C during 15 min. Next, it was added through a cannula to the azide-alkyne 
reaction mixture. The resulting reaction mixture was stirred at 45º C during 2 days. After this, 
a mixture of brine (50 mL) and water (50 mL) was added and the product was extracted twice 
with ethyl acetate (2 x 70 mL). The organic phase was washed three times with a mixture of 
brine (75 mL) and water brine (25 mL), once with a KCN aqueous solution (15 mg into 100 
mL of water) and twice with brine (2 x 100 mL) and dried over anhydrous MgSO4. The 
solvent was removed under reduced pressure and the crude product purified through silica 
gel column chromatography (dichloromethane : methanol = ramp from 100:0 to 96:4). The 
product was further purified by dialysis (MWCO = 1000 Da) in methanol during 24 hours, to 
obtain a white powder (334 mg; yield = 27%). 
Mw = 3032.54 g/mol. 
1H NMR (400 MHz, CDCl3) δ (ppm): 7.74 (s, 1H, H-24), 6.43 (bs, -NHCO), 5.38 (bs, -
NHBoc), 5.25 (s, 2H, H-26), 4.39 (t, J = 6 Hz, 2H, H-23), 4.26 (m, 32H, H-6, H-10, H-14 and 
H-30), 4.20 (t, J = 6 Hz, 2H, H-18), 3.88 (s, 20H, H-4 and H-32), 2.24 (t, J = 8 Hz, 4H, H-34), 
1.80 (t, J = 5 Hz, 2H, H-22), 1.44 (s, 72H, H-1), 1.28 (s, 12H, H-8), 1.25 (s, 40H, H-12, H-16, 
H-29 and H-36), 0.88 (t, J = 6.8 Hz, 6H, H-37). 
13C NMR (100 MHz, CDCl3) δ (ppm): 173.89 (C-9), 172.43 (C-13), 172.17 (C-17), 172.00 (C-
27), 171.69 (C-33), 170.23 (C-31), 169.73 (C-5), 156.04 (C-3), 80.06 (C-2), 65.83 (C-10, C-
14, C-18 and C-30), 65.5 (C-6), 46.53 (C-7, C-11, C-15 and C-28), 42.36 (C-32), 41.19 (C-4), 
36.41 (C-34), 32.04 (C-22), 29.82 (C-19 and C-35), 29.65 (C-12, C-16 and C-29), 28.45 (C-
1), 25.70 (C-21), 22.80 (C-20), 18.05 (C-36), 17.68 (C-8), 14.24 (C-37). 
FTIR (νmax/cm-1, ATR): 3370 (N-H st), 2922 and 2852 (C-H st), 1742 (C=O st ester), 1718 
(C=O st carbamate), 1522 (N-H δ), 1470 (CH2, CH3 δ), 1367 (C-N st), 1157 (N-CO-O st). 
MS (ESI+) m/z (%): found 3055.8 (100), calculated for [C145H243N13O54,Na]+ 3053.66. 
EA (%): Found: C. 57.15; H. 8.94; N, 5.78. Calc. for C145H243N13O54: C, 57.43; H, 8.08; N, 
6.00.  
GPC: (ref PMMA): Mw 6346 g.mol-1;  Ð 1.05. 
 
Synthesis and characterization of the deprotected dendrimer ((NH3+Cl-)8[bisMPA,G3]-
[bisGMPA,G1](C17)2): deprotection of the amino terminal groups 
 
Figure 6: Skeletal structure of (NH3+Cl-)8[bis-MPA,G3]-[bis-GMPA,G1](C17)2. 
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(NHBoc)8[bisMPA,G3]-[bisGMPA,G1](C17)2 (280 mg, 92.33 µmol) was dissolved into ethyl 
acetate (2 mL). Hydrochloric acid into ethyl acetate (3M, 6 mL) was added to it. The reaction 
mixture was stirred at room temperature during 45 minutes until a white precipitate appeared. 
It was then diluted into ethyl acetate and stirred during another 30 minutes. The hydrochloric 
acid was removed under vacuum. The reaction mixture was centrifuged and the precipitate 
was recovered and washed twice with pure ethyl acetate. The product was finally obtained 
as a white powder (220 mg, yield = 94%). 
Mw = 2523.30 g/mol. 
1H NMR (400 MHz, MeOD) δ (ppm): 8.10 (s, 1H, H-21), 5.27 (s, 2H, H-23), 4.50 – 4.39 (m, 
18H, H-3 and H-20), 4.40 – 4.22 (m, 16H, H-7, H-11 and H-27), 4.15 (t, J = 6.0 Hz,  2H, H-
15), 3.96 (s, 16H, H-1), 3.88 (s, 4H, H-29), 2.26 (t, J = 7.0 Hz, 4H, H-31), 1.95 (m, 2H, H-19), 
1.69 (m, 2H, H-16), 1.62 (m, 4H, H-32), 1.45 (m, 4H, H-17 and H-18), 1.33 (s, 12H, H-5), 
1.29 (m, 65H, H-9, H-13 and H-33), 1.25 (s, 3H, H-26), 0.90 (t, J = 6.6 Hz, 6H, H-34). 
13C NMR (100 MHz, MeOD) δ (ppm): 176.79 (C-6), 173.93 (C-10), 173.75 (C-14), 173.37 (C-
24), 173.23 (C-30), 170.84 (C-28), 168.39 (C-2), 143.57 (C-22), 126.22 (C-21), 67.58 (C-7, 
C-11, C-15 and C-27), 66.82 (C-3), 59.05 (C-23), 51.34 (C-20), 47.60 (C-4, C-8, C-12 and C-
25), 41.92 (C-29), 41.15 (C-1), 36.78 (C-31), 33.05 (C-19), 31.12 (C-16 and C-32), 30.87 – 
30.07 (C-9, C-13 and C-26), 26.95 (C-18), 26.44 (C-17), 23.71 (C-33), 18.17 (C-5), 14.45 (C-
34). 
FTIR (νmax/cm-1, ATR): 3674-3202 (N-H st), 3202-2600 (N-H+ st), 2962-2920-2851 (C-H st), 
1734 (C=O st ester), 1647 (C=O amide st), 1472 (CH2, CH3 δ), 1217 (C-O st), 1128 (O-C-C 
st). 
MS (ESI+) m/z (%): found 2254.0 (100), calculated for [C105H179N13O38,Na]+ 2253.24. 
EA (%): Found: C. 48.54; H. 8.35; N, 6.8. Calc. for C105H187N13O38Cl8: C, 49.98; H, 7.47; N, 
7.22.  
 
4.2 - Formation of aggregates 
The formation of aggregates of the amphiphilic dendrimer was carried out by the oil-in-water 
method[14]. The dendrimer was dissolved at a concentration of 1 mg/mL in dichloromethane. 
An identical volume of distilled water to that of dichloromethane was added. The mixture was 
stirred at room temperature with an IKA KS 130 basic orbital shaker until the organic solvent, 
which is highly volatile and water-immiscible, had completely evaporated. The final 
concentration of the dendrimer in water was 1 mg/mL. 
 
4.3 - Drug encapsulation 
Encapsulation of camptothecin, tiratricol and iopanoic acid inside the aggregates was carried 
out by means of the solvent diffusion technique[15]. In the case of camptothecin, a solution of 
the drug into DMSO (200 µg/mL) was added to the previously prepared aggregates (in 
aqueous medium), so that the final solution contained 100 µg of camptothecin per mg of 
dendrimer. In the case of tiratricol and iopanoic acid, a solution of the drug into DMSO (1 
mg/mL) was added to the aggregates, so that the final solution contained 500 µg of the drug 
per mg of dendrimer. In all cases the volume of DMSO added was equal to half the volume 
of water. The mixtures were stirred at 4° C for 12 h, allowing the drug to reach the lipophilic 
core of the aggregates. DMSO was removed by dialysis against distilled water at 4° C using 
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a 1000 Da membrane. The non-encapsulated drugs (especially camptothecin) precipitated 
during the dialysis and were removed by filtration to obtain the dendrimer/CPT aggregates. 
The concentration of encapsulated camptothecin was measured by fluorescence (λmax = 436 
nm and λexc = 368 nm). 100 µL of the filtered solution were dissolved into 1900 µL of DMSO 
in order to break the aggregates and ensure drug release. The intensity of the fluorescence 
maximum was compared to a calibration curve ranging from 0 ng/mL to 50 ng/mL. The 
concentration of encapsulated tiratricol and iopanoic acid was measured by UV-Vis 
absorbance (tiratricol λmax = 300 nm; iopanoic acid λmax = 317 nm). The samples were diluted 
into DMSO (1:3) in order to break the aggregates and ensure drug release, without allowing 
DMSO absorbance to affect the measurements. The intensities of the absorbance maxima 
were compared to a calibration curve ranging from 0 µg/mL to 170 µg/mL. The fluorescence 
emission spectra were obtained on a Perkin-Elmer-Ls 55 system. The UV–Vis absorbance 
spectra of the samples were measured with a Varian Cary 50 probe UV–Vis 
spectrophotometer. The calibration curves for the three compounds can be found in the 
Annex (figure A33). 
 
4.4 - Dynamic light scattering (DLS) 
This technique that allows to determine the size distribution profile of particles in a solution. It 
generates data by measuring the light scattering produced when a laser beam hits spherical 
particles. 
The nanoaggregates both empty and encapsulating the drugs were studied with a Malvern 
Instruments Nano ZS that uses a He-Ne laser with a wavelength of 633 nm and a detection 
angle of 173°. 
 
4.5 - Transmission electron microscopy (TEM) 
TEM images and measurements were obtained using the bright field operation mode. The 
samples were prepared by depositing a drop of an aqueous solution containing the 
dendrimeric aggregates or the dendrimer/drug conjugates on a holey carbon film 300 Mesh 
Cu (50) grid from Agar Scientific. The liquid was removed and the sample was stained with 
an aqueous solution of phosphotungstic acid (3%). After the liquid was removed, the 
samples were allowed to dry for at least 24 hours. 
The TEM experiment was performed in a TECNAI G20 (FEI COMPANY), 200 kV, at the 
Laboratory of Advanced Microscopy (LMA) of the INA (Nanosciences Institute of Aragon). 
Width value for each drug/carrier conjugate was calculated as the mean of the widths of 50 
different micelles measured on 5 different images. 
 
4.6 - Isothermal titration calorimetry (ITC) 
This technique that studies the thermodynamic interactions between two molecules, allowing 
to determine directly Ka, ΔH and N of the interaction. The apparatus consists of two cells 
(sample cell and reference cell) and a syringe that injects aliquots of a ligand sequentially 
into the sample cell, which are then stirred. What is measured is the thermal power needed 
to maintain the reference cell and the sample cell at an identical temperature against time[16]. 
The reference cell contains water or buffer solution, while the sample cell contains a 
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molecule which, upon interaction with the ligand, releases or absorbs heat. In this case, the 
equipment in which the measurements were carried out was an Auto-iTC200 Isothermal 
Titration Calorimetry (MicroCal, GE Healthcare). 
 
 
Figure 7: Schematic drawing of the basic functioning of an ITC experiment (A) and an ITC 
equipment (B). Images taken from the apparatus’s comercial brochure (Malvern). 
 
The syringe was fed 150 µL of the drug solution (final concentration = 100 µM). The sample 
cell was fed 400 µL of a solution containing the dendrimer (final concentration = 10 µM). A 
pre-rinse solution was also prepared containing the same composition as that used for the 
sample cell except for the molecules involved in the interaction. 







Table 1: Concentrations and volumes used for the ITC experiments. 
 
4.7 - Cell cultures 
The cell studies carried out in this work were performed on cells of the Huh 5-2 line. They are 
obtained by transfecting the subgenomic HCV replicon I389luc-ubi-neo/NS3-3’/5.1 into the 
highly permissive cell clone Huh 7-Lunet, established from a hepatocellular carcinoma[17]. 
The replicon system mimics the viral replication cycle, and allows to assess the effects of 
drugs on viral replication while minimizing the risks of working with viable viral particles. It 
contains the sequence encoding HCV non-structural proteins that are essential for replication 
(codifying region from NS3 to 3’-NTR), along with a selection system consisting of a reporter 
gene, Photinus spyralis luciferase, and the antibiotic resistance marker neomycin 
phosphotransferase, which confers resistance to geneticin (G418). The genetic construction 
also contains the 5’-NTR region of the encephalomyocarditis virus (ECMV) and an internal 
ribosome entry site[18]. 
 Cell Syringe Pre-rinse 
Milli-Q water 386 µL 148.5 µL 396 µL 
DMSO 4 µL - 4 µL 
Drug (10 mM in DMSO) - 1.5 µL - 





Figure 8: Genome of the HCV: regions and proteins coded[19] (A); genetic 
construct of the replicon system contained in Huh 5-2 cells[20] (B). 
 
 
Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with or without phenol 
red, supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin, 100 
µg/mL streptomycin, and 250 µg/mL geneticin (G418), under conditions of constant 
temperature (37º C), pressure (1 atm) and CO2 concentration (5% CO2, 95% air). 
Since Huh 5-2 cells are adherent, incubation with trypsin-EDTA 0.05% (5-10 minutes at 37º 
C) was necessary prior to subcultivations. PBS was used to eliminate cell residues. All cell 
culture media and reagents used were pre-warmed at 37º C so as not to affect cell 
metabolism, and all manipulations were carried out in a laminar flow hood, respecting all due 
precautions in order to avoid contaminations. 
DMEM (Dulbecco’s modified Eagle’s medium, 4.5 g/L glucose), DPBS (Dulbecco’s 
phosphate-buffered saline) and geneticin (G418) were purchased from Gibco. Penicillin/41 
streptomycin (5000 U/mL) and trypsin-Versene (EDTA) were purchased from Lonza. Fetal 
bovine serum was purchased from PAN-Biotech GmbH. 
 
4.8 - Cell assays: viability and viral inhibition 
For these assays cells were seeded at a density of 7000 cells per well in the complete 
DMEM medium without phenol red in a 96-well plate (white plates in the case of the viral 
inhibition assay and transparent plates in the case of the cell viability assay). Cell 
concentration was determined using a Scepter™ 2.0 Cell Counter (Millipore). They were 
allowed to grow for 24 hours. After this the medium was removed. 
Solutions containing different concentrations of the drugs, dendrimer/drug conjugates or the 
dendrimer aggregates and 2% DMSO in complete DMEM medium without phenol red were 
prepared. Triplicates of each concentration were made by adding 100 µL per well of the 
different solutions. The cells were then incubated for 72 hours prior to the realization of the 
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assays. A scheme representing the setup of the plates can be found in the annex (figure 
A34). 
To assess the cytotoxicity of both the drugs and the dendrimer, cell metabolism levels were 
determined using Promega’s Cell Titer 96®AQueous kit. It is a colorimetric method based on 
the conversion of MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium salt) into formazan, which only occurs in living cells, due to the 
activity of the succinate-tetrazolium reductase (Technical Bulletin CellTiter 96® AQueous 
One Solution Cell Proliferation Assay). For this assay, 20 µL of the CellTiter 96® AQueous 
One Solution Reagent were added to each well, and the plates were incubated for an hour 
and a half in the conditions described in the previous section. Absorbance of the formazan 
products was then measured at 490 nm in a Synergy™ HTX Multi-Mode Microplate Reader. 
Absorbance at 800 nm (non-specific) was also measured and subtracted from the 
absorbance at 490 nm (specific). Data were obtained using the Gen5™ Data Analysis 
software. The 50% cytotoxic concentration (CC50) was calculated as the drug concentration 
that reduced cell viability by 50% compared to untreated controls. 
The antiviral activity of the different compounds was determined using Promega’s Bright-
Glo™ Luciferase Assay System kit. This kit allows to indirectly measure the replication rate 
of the HCV replicon system of the Huh 5-2 cells. These cells express luciferase and 
neomycin phosphotransferase as a fusion protein. If the viral serin-protease NS3 is 
expressed, luciferase is released and free to oxidize its specific substrate, luciferin (present 
in the Bright-Glo™ Luciferase Assay Substrate). This reaction is carried out in the presence 
of Mg2+, ATP and O2, and yields oxyluciferin, which is fluorescent. The formation of this 
product results in a luminiscence signal that is proportional to the quantity of RNA from the 
replicon system that is being expressed (Technical Manual Bright-GloTM Luciferase Assay 
System). For this assay, 20 µL of the Bright-Glo™ Luciferase Assay Substrate were added to 
each well, and the plates were incubated for an hour and a half in the conditions described in 
the previous section. Luminiscence was measured in a Synergy™ HTX Multi-Mode 
Microplate Reader. Data were obtained using the Gen5™ Data Analysis software. The 50% 
inhibitory concentration (CC50) was calculated as the drug concentration that inhibited viral 
replication by 50% compared to untreated controls. 
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5 - RESULTS AND DISCUSSION 
5.1 - Synthesis of the bis-GMPA lipophilic dendron 
A new lipophilic bis-GMPA dendron bearing an alkyne group at its focal point and two 
terminal aliphatic linear chains of seventeen carbons (C17) was synthesized. The pathway 
followed is represented in the next scheme (all of the molecules except the precursors were 
synthesized as part of this work; the synthetic procedures and results of their 
characterization can be found in the Annex): 
 
 
Figure 9: Synthesis scheme of reactions leading to the bis-GMPA lipophilic dendron (molecule 5). 
 
The propargyl group was inserted at the focal point of the acetal-protected bis-MPA 
monomer by means of a Steglich esterification (molecule 1). Following reductive deprotection 
(molecule 2), the same kind of reaction was carried out in order to introduce the internal 
glycine moieties (molecule 3). After the amino-terminal groups were deprotected (molecule 
4), the dendron was functionalized with the aliphatic chains by means of an amidation 
between the amino-terminal groups and stearic acid, again following conditions similar to 
those of a Steglich reaction. 
In general, the Steglich esterifications were carried out under Argon atmosphere using 
anhydrous dichloromethane as solvent. In this kind of reaction, DCC 
(dicyclohexylcarbodiimide) acts as a coupling agent and is transformed into DCU 
(dicyclohexylcarbodiurea), which needs to be removed by precipitation in hexane and 
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filtration. DPTS (4-(dimethylamino)pyridium 4-toluenesulfonate) acts as a catalyst and is 
regenerated after the esterification. The crude products must be purified by flash 
chromatography on silica gel. 
In the case of the reaction yielding the final dendron (molecule 5), some modifications of this 
protocol were made: HOBt (hydroxybenzotriazole) was also used as a coupling agent, and 
DPTS was substituted by DMAP (4-(dimethylamino)pyridine). This reagent neutralizes the 
acidic ammonium salts of the dendrons, favoring the amidation. In addition, anhydrous 
DMSO (dimethyl sulfoxide) was employed to dissolve the precursor compound (4). 
Each of the molecules was characterized by 1H and 13C nuclear magnetic resonance (NMR), 
mass spectrometry (MS), Fourier transform infrared spectroscopy (FTIR) and elemental 
analysis (EA), in order to assess their integrity and purity. 
In particular, the following 1H NMR results confirmed that the synthesis and functionalization 
of the final dendron had been successful: 
• The appearance of four peaks at 0.87, 1.24, 1.63 and 2.23 ppm, corresponding 
respectively to the terminal methyl proton (0.87 ppm) and to the methylene protons 
(rest of the peaks) of the aliphatic chain indicated the incorporation of the stearic acid. 
• The shift of the peak corresponding to the N-H proton from 8.56 ppm (in the 1H NMR 
spectrum obtained for molecule 4) to 6.16 (in the 1H NMR spectrum obtained for 
molecule 5) further confirmed that amidation between the amino-terminal groups 
present in molecule 4 and the stearic acid had taken place. 
• In addition, peaks corresponding to the protons of the propargyl moiety (a triplet at 
around 2.50 ppm and a doublet at around 4.72 ppm) could be observed in the spectra 
of all the molecules (1-5). 
 
5.2 - Synthesis of the amphiphilic Janus dendrimer 
The synthesis of the dendrimer was carried out by linking the lipophilic dendron with a bis-
MPA hydrophilic dendron (molecule 6), previously synthesized by Dr Alexandre Lancelot as 
part of the work of his PhD thesis[13]. 
This was achieved by means of a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 
through which the alkyne group of the lipophilic dendron and the azide group of the 
hydrophilic dendron are joined to form a triazole ring. This can be considered a “click 
chemistry” reaction. 
The Cu(I) catalyst was formed in situ by reduction of the copper (II) salt with (L)-ascorbate, 
and stabilized by TBTA (tris(benzyltriazolylmethyl) amine). Anhydrous DMF (dimethyl 
formamide) was used as solvent. The reaction took place at 45º C during 24 hours. 
The purification of this product (molecule 7) was rather challenging and required several 
steps. The crude product first underwent several washings with brine and an aqueous KCN 
solution. Next, it was purified by flash chromatography on silica gel. The final level of purity 
was achieved through dialisis against methanol. 
The acid-mediated cleavage of the t-Boc protective groups yielded the final amphiphilic 
Janus dendrimer (molecule 8). 
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These molecules were likewise characterized by 1H and 13C NMR, MS, FTIR and EA. The 
main result that allowed to confirm the correct synthesis of the dendrimer was the 
appearance in the 1H NMR spectrum of the peak corresponding to the proton of the triazole 
ring, at 7.74 ppm in the spectrum corresponding to molecule 7 and at 8.10 ppm in the 
spectrum obtained for molecule 8. 
The monodispersity of the lipophilic dendron and the Janus dendrimer was confirmed by gel 
permeation chromatography (GPC). Dispersity values (Ð) obtained were of 1.04 for the 
lipophilic dendron (molecule 5) and 1.05 for the Janus dendrimer (molecule 8).  
 
 
Figure 10: Synthesis scheme of reactions leading to the Janus dendrimer (molecule 8). 
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5.3 - Formation of dendritic aggregates and drug encapsulation 
The property of self-assembling in aqueous solution of amphiphilic Janus dendrimers was 
exploited to create structures that could function as drug carriers. These, in turn, were used 
to encapsulate three different drugs: camptothecin (CPT), tiratricol (TRIAC) and iopanoic 
acid (IA). 
As a first step, aggregates were created using the oil-in-water technique. In this technique, 
an emulsion is formed composed by a volatile organic solvent in which the dendrimer is 
dissolved (in this case, dichloromethane) and water. Constant stirring allows the dendrimer to 
slowly diffuse into the water, forming aggregates as concentration increases due to its 
amphiphilic properties. The organic solvent evaporates over time, finally leaving an aqueous 
solution where dendritic aggregates are suspended. These aggregates have a lipophilic core 
and a hydrophilic shell (exterior), a characteristic that makes them appropriate for 
transporting hydrophobic substances in a physiological medium. 
In order to encapsulate the pharmacological compounds within the nanocarriers, the solvent 
diffusion technique was used. It consists on adding a solution of the drug in DMSO to the 
aqueous solution containing the dendritic aggregates and stirring during a sufficient amount 
of time for the drug to reach the lipophilic core of the carriers (approximately twelve hours). 
DMSO is then removed by dialysis. The drug that is not encapsulated precipitates in water 
and is removed by filtration. 
It was estimated that the drug/dendrimer proportion of the resulting conjugates would be 
lower for camptothecin than for tiratricol and iopanoic acid, given the more rigid structure of 
this drug. For this reason, the feeding ratio used for camptothecin was 0.1/1 
(weightdrug/weightdendrimer), whereas for tiratricol and iopanoic acid it was 0.5/1 
(weightdrug/weightdendrimer). Each of the three drug/dendrimer conjugates was prepared by 
duplicate. 
The amount of drug encapsulated in the nanocarriers was determined by fluorescence in the 
case of CPT and by UV-Vis absorbance in the case of TRIAC and IA. The results are 
recorded in table 2. 
 
 
Table 2: Drug/dendrimer weight-to-weight ratio, molar ratio and encapsulation efficiency (EE: 
percentage of drug mass encapsulated with respect to initial drug mass) of the different conjugates. 
 
The results of camptothecin encapsulation in the new dendrimer, composed by a hydrophilic 
bis-MPA dendron and a lipophilic bis-GMPA dendron, surpass those observed in the 
precedent research[13]. Janus dendrimers composed of hydrophilic and lipophilic dendrons 
Drug Conjugate weightdrug/weightdendrimer moldrug/moldendrimer EE (%) 
CPT 
1 0.08 0.55 76 
2 0.07 0.48 66 
TRIAC 
3 0.34 1.38 68 
4 0.36 1.48 73 
IA 
5 0.31 1.39 63 
6 0.33 1.47 67 
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based on bis-MPA had yielded camptothecin encapsulation efficiencies of up to 14%. The 
ones composed by hydrophilic bis-GMPA dendrons and lipophilic bis-MPA dendrons 
improved camptothecin encapsulation efficiencies up to a maximum of 61%. The new 
dendrimer shows the ability to encapsulate an amount of camptothecin much superior to the 
bis-MPA/bis-MPA dendrimers, and slightly higher than the bis-GMPA/bis-MPA dendrimers. 
With regard to tiratricol and iopanoic acid, encapsulation in Janus dendrimers based on bis-
MPA or bis-GMPA dendrons had not been attempted. The new dendrimer also presents a 
high efficiency in encapsulating these compounds.  
The good results obtained for this dendrimer further confirm that inclusion of a glycine moiety 
can improve drug encapsulation, arguably because it introduces the possibility of the 
formation of hydrogen bonds and other interactions between the drug and the carrier. 
Dendrimers composed of dendrons of different generations should also be studied. However, 
it is to be noted that the dendrimers that had yielded the best encapsulation efficiencies in 
the past were composed of lipophilic dendrons of the lowest generation (2 terminal aliphatic 
chains) and hydrophilic dendrons of eight amino-terminal groups, a structure similar to that of 
the dendrimer described in this work. 
 
5.4 - Study of the size and morphology of the nanoaggregates 
The aggregates, both empty and encapsulating the three different drugs, were characterized 
by transmission electron microscopy (TEM) and dynamic light scattering (DLS). 
TEM imaging was employed to determine the morphology of the nanoaggregates. In this 
technique a beam of electrons is transmitted through a material; the differential behavior of 
electrons depending on the characteristics of said material allows to obtain an image. 
 
Figure 11: Images of the empty aggregates (A), the CPT-loaded 
aggregates (B), the TRIAC-loaded aggregates (C) and the IA-
loaded aggregates (D) obtained by TEM. Scale = 20 nm. 
19 
As the bright field operation mode was used, the contrast of the images depends on the 
thickness, density or atomic number of the sample: the higher these are in a certain region, 
the darker this region will appear. Thus, the areas of the grid that have been stained with 
phosphotungstic acid appear dark in the images, due to the presence of tungstene, a heavy 
metal. Areas where nanoaggregates are adsorbed will be devoid of the phosphotungstic 
acid, and will appear bright. It is important to note that the images obtained are therefore not 
a direct representation of the aggregates. 
In all cases the aggregation of the dendrimer appears to have resulted in spherical micelles. 
This morphology remains unchanged as a result of drug encapsulation. It can also be 
observed that while the other aggregates (A, B and C in figure 11) appear to be isolated, the 
micelles containing iopanoic acid (D in figure 11) seem to interact forming a reticular pattern. 
The size of the particles was measured both on the TEM images and by DLS. 
DLS provided a value of the hydrodynamic diameter (diameter of a hypothetical hard sphere 
that presents the same diffusional behavior as that of the dynamic hydrated or solvated 
particle measured). The results obtained have been processed using two different 
mathematical approaches: number and intensity. The former is more sensitive to small 
particles, while the latter allows to detect bigger aggregations. 
The width values measured on TEM images and the DLS number and DLS intensity average 
data are presented in table 3. 
 
Aggregate 
TEM DLS (number) DLS (intensity) 
width DH DH 
Dendrimer 24 ± 4 nm 13 ± 2 nm 352 ± 160 nm 
CPT/dendrimer 23 ± 5 nm 696 ± 84 nm 681 ± 81 nm & 1869 ± 187 nm 
TRIAC/dendrimer 24 ± 4 nm 20 ± 5 nm 204 ± 131 nm 
IA/dendrimer 19 ± 3 nm  15 ± 3 nm 143 ± 34 nm & 631 ± 162 nm 
 
Table 3: Sizes of the empty or drug-loaded aggregates obtained by TEM or DLS (mean ± standard 
deviation). 
The DLS number values are consistent with those extracted from the TEM images, except 
for the ones obtained for the camptothecin/dendrimer conjugate. However, this can be 
explained by the fact that camptothecin is a fluorescent compound, so it interacts with light 
making DLS measurements not reliable. These results (TEM and DLS number) correspond 
to the  sizes of the isolated micelles. Particle size does not appear to vary significantly as a 
result of drug encapsulation, except for a slight shrinking observed in the microscopy images 
of the iopanoic acid/dendrimer conjugate. 
DLS intensity data indicate the presence of bigger aggregates[21]. These present a great 
dispersion in sizes, which translates into high standard deviations. It can therefore be 
deduced that these sizes correspond to clusters of micelles possibly formed due to non-
specific interactions. This effect is more noticeable in the case of iopanoic acid, where a 
population of aggregates of around 630 nm has been found (not counting the data 
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corresponding to the CPT/dendrimer conjugate, which are not reliable). This is coherent with 
the observations made regarding TEM images. 
 
5.5 - Isothermal titration calorimetry 
Isothermal Titration Calorimetry was used to analyze the thermodynamics of the interactions 
produced between the dendrimer and the different drugs. For this technique, a solution 
containing the dendrimer is placed inside the sample cell and a solution containing the ligand 
(camptothecin, tiratricol or iopanoic acid) is titrated into this cell until saturation of the 
dendrimer occurs. 
The amount of heat released or absorbed as a result of the interactions between both 
molecules is measured and represented in a thermogram (figure 11, top part). Each peak 
corresponds to one injection of ligand and is proportional to the amount of heat involved in 
the formation of the drug-dendrimer complex. The peaks are then integrated with respect to 
time and normalized for concentration to generate a titration curve representing kcal/mol vs 
ligand/sample molar ratio (figure 11, bottom part). 
 
 
Figure 12: Thermograms and titrations curves obtained by ITC, describing interaction between each 
of the drugs and the dendrimer. 
 
Binding affinity (Ka), enthalpy changes (ΔH), and binding stoichiometry (N) were calculated 
by fitting the titration curve to a binding model considering one set of ligand binding sites. 
The results are recorded in table 4. 
  CPT/dendrimer TRIAC/dendrimer IA/dendrimer 
Ka (M-1) 850000 ± 90000 550000 ± 30000 1800000 ± 70000 
ΔH (kcal/mol) 1360 ± 60 - 6000 ± 1000 - 2000 ± 200 
N (mol drug/mol dendrimer) 0.38 ± 0.01 0.78 ± 0.06 0.64 ± 0.03 
 
Table 4: Thermodynamic parameters calculated for each of the drug/dendrimer complexes (± 
standard deviation). 
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Iopanoic acid exhibits a higher affinity for the dendrimer in comparison with camptothecin 
and tiratricol. This could explain the smaller size of the micelles containing iopanoic acid and 
the higher aggregation  described between them (figure 11D and table 3). 
The ΔH value is positive for the CPT/dendrimer interaction and negative for the 
TRIAC/dendrimer interaction and the IA/dendrimer interaction. This could mean that in the 
case of camptothecin, hydrophobic interactions contribute more to the formation of the 
complex than specific interactions, while the opposite happens with the other two 
compounds. In absolute values, the greatest enthalpy change has been observed for the 
formation of the TRIAC/dendrimer complex.  
The highest binding stoichiometry has been found for the TRIAC/dendrimer complex, 0.78, 
followed by the IA/dendrimer complex, 0.64. The CPT/dendrimer complex presents the 
lowest binding stoichiometry, 0.38. There is a qualitative correlation between this and the 
drug/dendrimer molar ratios calculated for the encapsulated drugs (table 2), which were also 
lowest in the case of the carriers loaded with camptothecin. Binding stoichiometries and 
molar ratios, however, do not match quantitatively; this could be explained by the different 
conditions of time and concentration in which the processes of the titration and the 
encapsulation were carried out. 
 
5.6 - Cell viability and drug inhibition 
The purpose of encapsulating camptothecin, tiratricol and iopanoic acid within the 
nanocarrier was to enhance the activity of these drugs against the Hepatitis C virus. With 
respect to camptothecin, the aim was also to lower its cytotoxicity. Besides from assessing 
whether these objectives had been achieved, it was necessary to ensure that the dendrimer 
did not affect cell viability. The procedures followed are described in section 4.8 (pages 12-
13). In both assays, the effects of the encapsulated drug were compared to those of the free 
drug and to those of the free dendrimer. A negative control was used as a reference. 
Camptothecin 
Figure 13 compares the effects of free and encapsulated camptothecin on cell viability and 
viral replication. 
 
Figure 13: Viral replication (bars) and cell viability (lines) against concentration of encapsulated 
camptothecin (red) and free camptothecin (blue). The left vertical axis represents viral inhibition (%), 
the left vertical axis represents cell metabolism (%) and the horizontal axis represents CPT 




































The IC50 value could not be calculated due to the high inhibition values observed in this 
assay (above 70% and reaching 100%). Previous studies published in our group carried out 
with the same drug concentrations reported an IC50 value of 0.3 µM for free 
camptothecin[11]. Concerning cell viability, the CC50 value of free camptothecin estimated as 
a result of this work coincides with the value reported in these previous studies, 0.6 µM. It 
can therefore be inferred that the higher levels of viral inhibition observed are not the result of 
a lower cell viability. 
The antiviral activity of the encapsulated drug is similar to that of the free drug, albeit slightly 
higher. At low CPT concentrations (0.03 - 0.13 µM), viability remains higher for cells treated 
with the encapsulated drug. This suggests that using the new dendrimer as a drug carrier 
could broaden the therapeutic window of camptothecin, allowing to obtain results of viral 
inhibition similar to those obtained with the free drug but with a lower cytotoxicity. These 
results must nonetheless be confirmed, especially since they differ from what was observed 
in previous studies. 
Tiratricol and iopanoic acid 
HCV replication assays did not yield representative results, since a direct correlation 
between viral inhibition and drug concentration (either free or encapsulated) could not be 
determined. However, encapsulation in the dendritic aggregates seemed to increase the 
antiviral activity of these drugs. Again, the free form of these compounds showed a higher 
activity in this assay compared to data observed in the previous studies[7]. The IC50 values 
estimated as a result of this assay were of 7.25 µM for tiratricol and of 7.50 µM for iopanoic 
acid, whereas the reported IC50 values were of around 25 µM for tiratricol and of >120 µM 
for iopanoic acid. With respect to cell viability, the assays showed that no cytotoxicity was 
derived from these drugs or the corresponding drug/dendrimer conjugates. 
As a summary, IC50 and CC50 values estimated for the free compounds and the 
encapsulated compounds are represented in table 5. Cells incubated with the free dendrimer 
at the same concentrations present in the assays carried out with encapsulated drugs did not 
exhibit any viral inhibition or viability reduction (data not shown). 
Compound IC50 (µM) CC50 (µM) Free drug Encapsulated drug Free drug Encapsulated drug 
CPT < 0.03 < 0.03 0.60 0.25 
TRIAC 7.25 1.25 > 120 > 120 
IA 7.50 5.00 > 120 > 120 
Table 5: IC50 and CC50 of the free and encapsulated compounds determined in this experiment. 
Errors in all cases are comprised within an interval of 5-10%. 
Camptothecin, tiratricol and iopanoic acid all showed unusually high antiviral activities in this 
experiment. This suggests that there could be a problem related to the replicon system of the 
Huh 5-2 cells: for instance, the number of replicon copies per cell could have decreased. 
Hence, it is necessary to repeat the experiment after selecting and increasing the number of 
replicon copies in the cell line. 
This can only be considered a preliminary study. As a general rule, due to the great number 
of variables that condition an experiment with living cells, it is important to repeat these 
assays in several different occasions in order to obtain reproducible results. 
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6 - CONCLUSIONS / CONCLUSIONES 
The following conclusions can be drawn from the results obtained throughout this project:  
• A new lipophilic dendron based on bis-GMPA has been synthesized. This building block 
has led to the synthesis of an amphiphilic Janus dendrimer composed by the bis-GMPA 
lipophilic dendron and a bis-MPA hydrophilic dendron. 
• The new dendrimer has been proved to form micellar aggregates in water. These   
aggregates are able to encapsulate camptothecin, tiratricol and iopanoic acid with a high 
efficiency, improving the results obtained with Janus dendrimers in previous studies. 
• Encapsulation of the different drugs does not significantly change the properties of size 
and morphology of the dendritic aggregates. 
• Isothermal titration calorimetry has allowed to describe the interaction between the 
different drugs and the dendrimer. The thermodynamic parameters of the interaction 
processes have been determined. 
• The dendrimer does not seem to affect cell viability in vitro. Cell viability after incubation 
with the drug/dendrimer conjugates was also seen to be adequate. 
• The anti-HCV activity of the drugs encapsulated in the new nanocarrier could not be 
appropriately determined. 
 
Se pueden extraer las siguientes conclusiones de los resultados obtenidos a lo largo de 
este proyecto: 
• Se ha sintetizado un nuevo dendrón lipófilo basado en bis-GMPA. Este bloque básico ha 
permitido la síntesis de un dendrímero Jano anfifílico compuesto por el dendrón lipófilo 
de bis-GMPA y un dendrón hidrófilo de bis-MPA. 
• Se ha comprobado la capacidad de formar micelas en agua del nuevo dendrímero. Estos 
agregados son capaces de encapsular camptotecina, tiratricol y ácido iopanoico con una 
alta eficiencia, mejorando los resultados obtenidos con dendrímeros Jano en estudios 
anteriores. 
• La encapsulación de los diferentes fármacos no cambia de manera significativa las 
propiedades de tamaño y morfología de los agregados dendríticos. 
• Se ha podido describir la interacción entre los distintos fármacos y el dendrímero por 
calorimetría isotérmica de titulación. Los parámetros termodinámicos de los procesos de 
interacción se han determinado. 
• El dendrímero no parece afectar a la viabilidad celular in vitro. Se ha observado 
asimismo que la viabilidad celular tras la incubación con los complejos 
fármaco/dendrímero es adecuada. 
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